吕春婉博士于2020年11月加入天津大学生命科学院，主要研究成果以一作/通讯作者发表在ACS Nano,J Natl Cancer Inst (JNCI), J Immunother Cancer,  Cancer Immunol Res, Oncogene, Cancer Lett，OncoImmunology等肿瘤免疫学领域权威期刊上。先后入选天津市“科技咨询专家（青年项目）”和天津大学“北洋学者”英才计划。担任天津市免疫学会理事，Clinical and Translational Medicine，Frontiers in Immunology, Therapeutic Advances in Medical Oncology，Aging等多家权威学术期刊的独立审稿人、英国胰腺癌研究基金（UK Pancreatic Cancer Research Fund）外审专家、国家自然科学基金委员会通讯评审专家和著名免疫学期刊Frontiers in Immunology 副主编。指导学生获得国家奖学金、三好学生、天津大学优秀毕业生，天津大学优秀硕士毕业论文等。主要学术成果总结如下：

2 

本课题组的研究方向和思路是揭示胰腺癌和结直肠癌免疫逃逸和对免疫检查点阻断疗法耐受的分子机制，研发基于分子机制的新型免疫治疗药物，并将其转化至临床试验。如图所示：

一、主持项目

1. 2026年   企业横向项目II   主持  

2. 2026年  天津大学自主创新基金     主持   

3. 2025年  天津大学医学+项目       合作负责人  

4. 2024年   企业横向项目I     主持      

5. 2022年  国家自然科学基金面上项目   主持   

6. 2021年  天津市师资队伍建设项目      主持   

7. 2019年  国家自然科学基金青年项目    主持   

8. 2018年  美国国立卫生研究院R43项目   主持   

二、获奖

1.2025年天津市优秀硕士学位论文指导教师

2.2025年天津大学高水平自然科学类科技创新奖——青年科创潜力奖

3.2025年天津大学优秀硕士学位论文指导教师

4.2024年天津大学优秀硕士学位论文指导教师

5. 2021年天津大学生命科学院第二届青年教师讲课大赛特等奖

6. 2020年天津大学“北洋学者”英才计划

7. 2018年天津市科技咨询专家（青年项目）

8. 2020年美国免疫学会青年科学家旅行奖

9. 2019年美国免疫学会Chambers-Thermo Fisher科学纪念奖

10. 2017年第52届美国东南地区脂质会议优秀口头报告奖

11. 2017年美国免疫学会优秀墙报奖

三、部分科研论文

1. Yanmin Wu, ...., Chunwan Lu*. 5-FU chemotherapy induces functional CD7⁺ and IL7R⁺ CTLs infiltration to suppress colorectal tumor progression. Science China Life Science. 2026 Jul 16. *Corresponding author at Tianjin University. 

2. Yan Li, ...., Chunwan Lu*. 2025. IFNβ-pSTAT1-IRF1 axis controls colorectal tumor development through induction of immunogenic Ly6C⁺ myeloid cells. Neoplasia. 2026 Jan:71:101261. *Corresponding author at Tianjin University.   

3. Chunwan Lu*, et al. 2025. Slc7a5 promotes T cell anti-tumor immunity through sustaining cytotoxic T lymphocyte effector function. Oncogene. 2025 Aug 26. DOI: 10.1038/s41388-025-03543-5. *Corresponding author at Tianjin University.  

4. Liyan Liang, ..., Chunwan Lu*. 2024. Type I Interferon Activates PD-1 Expression through Activation of the STAT1-IRF2 Pathway in Myeloid Cells. Cells. 2024 Jul 8;13(13):1163. doi: 10.3390/cells13131163. *Corresponding author at Tianjin University

 5. Kaidi Deng, ..., Chunwan Lu*. 2024. The Wdr5-H3K4me3 Epigenetic Axis  Regulates Pancreatic Tumor Immunogenicity and Immune Suppression. International Journal of Molecular  Science. 2024,25(16) 8773; https://doi.org/10.3390/ijms25168773. *Corresponding author at Tianjin University

6. Yingcui Yang, ..., Chunwan Lu*. 2024. Delivery of interferon b-encoding plasmid via lipid nanoparticle restores interferon b expression to enhance anti-tumor immunity in colon cancer. ACS Nano. 2024 Feb 6. Doi: 10.1021/acsnano.3c10972. *Corresponding author at Tianjin University

7. Yingcui Yang,..., Chunwan Lu*. 2023. 5-Fluorouracil Suppresses Colon Tumor through Activating the p53-Fas Pathway to Sensitize Myeloid-Derived Suppressor Cells to FasL⁺ Cytotoxic T Lymphocyte Cytotoxicity. Cancers (Basel). 2023 Mar 2;15(5):1563.  *Corresponding author at Tianjin University

8.  Chunwan Lu*, ..., Kebin Liu*. 2022.  H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth. Oncogene, 2022 Apr;41(18):2651-2662. PMCID: PMC9058223 *Co-corresponding author at Tianjin University

9. Chunwan Lu*, ..., Kebin Liu*. 2022. G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes. J Immunother Cancer. 10(1):e003543.PMCID: PMC8753452   *Co-corresponding author at Tianjin University

10.  Chunwan Lu*, ..., Kebin Liu*. 2021. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. J Immunother Cancer. 9:e002624. PMCID: PMC8323468.*Co-corresponding author at Tianjin University

 11.  Chunwan Lu*, ..., Kebin Liu*. 2020. p50  suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy. J Immunother Cancer. 8:e001365. PMCID: PMC7555101.*Co-corresponding author

 12. Chunwan Lu*, ..., Kebin Liu*. 2020. SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth. Cancer Lett. 476:87-96. PMCID: PMC7138631.*Co-corresponding author

 13.  Chunwan Lu*, ..., Kebin Liu*. 2019. Type I IFNs activates STAT3 to regulate effector expression of cytotoxic T lymphocyte effectors to suppress tumor development. J Immunother Cancer. 7:157. PMCID: PMC6589175.*Co-corresponding author

14.  Chunwan Lu*, ..., Kebin Liu*. 2019. SUV39H1 represses the expression of cytotoxic T lymphocyte effectors to promote colon tumor immune evasion. Cancer Immunol. Res. 7:414-427. PMCID: PMC6397681.

*Co-corresponding author 

 15.  John D. Klement, Amy V. Paschall, Priscilla S. Redd, Mohammed L. Ibrahim, Chunwan Lu, Dafeng Yang, Esteban Celis, Scott I. Abrams, Keiko Ozato, and Kebin Liu*. 2018. An Osteopontin/CD44 immune checkpoint controls CD8⁺ T cell activation and tumor immune evasion. J Clin Invest. 128:5549-5560. PMCID: PMC6264631.

 16.  Tsadik Habtetsion, Zhi-Chun Ding, Wenhu Pi, Tao Li, Chunwan Lu, Tingting Chen, Caixia Xi, Helena Spartz, Kebin Liu, Zhonglin Hao, Nahid Mivechi, Yuqing Huo, Bruce R Blazar, David H Munn, Gang Zhou*. 2018. Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death. Cell Metab. 28:228-242. PMCID: PMC6082691.

 17. Kebin Liu and Chunwan Lu*. 2018. Gut microbes modulate response to immune checkpoint inhibitor cancer immunotherapy. Transl Cancer Res. 7:S608-S610. PMCID: PMC6233902

 18. Chunwan Lu* et al. 2018. Contrasting Roles of H3K4me3 and H3K9me3 in Regulation of Apoptosis and Gemcitabine Resistance in Human Pancreatic Cancer Cells. BMC Cancer. 18:149. PMCID: PMC5801751.

19. Chunwan Lu* and Kebin Liu. 2017. Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy.  Trans Cancer Res. 6:S652-S654. PMCID: PMC6320224.

 20. Chunwan Lu, ..., Kebin Liu*. 2017. Jak-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. OncoImmunology. 6:e1291106. PMCID: PMC5384417.

 21. Chunwan Lu, ..., Kebin Liu*. 2017. The MLL1-H3K4me3 Axis-Mediated Up-Regulation of PD-L1 Contributes to Pancreatic Cancer Immune Evasion. J Natl Cancer Inst. 109:djw283. PMCID: PMC5291187.

 22. Chunwan Lu, ..., Kebin Liu*. 2016. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. OncoImmunology. 5:e1247135. PMCID: PMC5214087.